Loading...

Bio-Plex Pro™ RBM Apoptosis Immunoassays

1,232 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 11, 2013

For more info, visit http://www.bio-rad.com/yt/11/Bio-Plex.
In this webinar, Dr. Dominic Eisinger describes the development and validation of a multiplex biomarker panel for quantifying the commitment, onset, and induction of apoptosis by the intrinsic pathway in tumor tissue samples.

Fourteen bead-based immunoassays for apoptosis-associated proteins were developed on the Myriad RBM multi-analyte profile (MAP) platform, which is based on Luminex xMAP technology. All assays were confirmed by IP-western blotting with the same antibody pairs used in the bead-based sandwich assays.

The assays were manufactured as three panels:
Panel 1: BAK, BAX, lamin B (intact +45 kDa), and SMAC
Panel 2: BAD, BAX/BCL-2 heterodimer, BCL-xl, BIM, and Mcl-1
Panel 3: Active caspase-3, BCL-xl/BAK heterodimer, MCL-1/BAK heterodimer, pBAD, and survivin

Each assay was validated for precision, linearity, and accuracy for use with tumor biopsies, cell lysates, and tissue lysates. The quantitative assays were found to be more sensitive than IP-westerns.

Presenter:
Dominic Eisinger, PhD
Director of Strategic Development, Myriad RBM

Brought to you in partnership with Myriad RBM.

http://www.bio-rad.com/en-us/category...

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...